0001127602-15-028793.txt : 20151007
0001127602-15-028793.hdr.sgml : 20151007
20151007170521
ACCESSION NUMBER: 0001127602-15-028793
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151005
FILED AS OF DATE: 20151007
DATE AS OF CHANGE: 20151007
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Alkermes plc.
CENTRAL INDEX KEY: 0001520262
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981007018
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN 4
STATE: L2
ZIP: 00000
BUSINESS PHONE: 00-353-1-772-8000
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN 4
STATE: L2
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC
DATE OF NAME CHANGE: 20110804
FORMER COMPANY:
FORMER CONFORMED NAME: Antler Science Two Ltd
DATE OF NAME CHANGE: 20110509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cooke Shane
CENTRAL INDEX KEY: 0001524823
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35299
FILM NUMBER: 151149492
MAIL ADDRESS:
STREET 1: TREASURY BUILDING LOWER GRAND CANAL ST.
CITY: DUBLIN 2
STATE: L2
ZIP: 00000
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2015-10-05
0001520262
Alkermes plc.
ALKS
0001524823
Cooke Shane
CONNAUGHT HOUSE
1 BURLINGTON ROAD
DUBLIN 4 IRELAND
1
President, Alkermes plc
Ordinary Shares
2015-10-05
4
M
0
12500
0
A
53140
D
Ordinary Shares
2015-10-05
4
F
0
6500
59.77
D
46640
D
Ordinary Shares
2015-10-05
4
A
0
7500
0
A
54140
D
Ordinary Shares
2015-10-05
4
F
0
3900
59.77
D
50240
D
Restricted Stock Unit Award
0
2015-10-05
4
M
0
12500
0
D
Ordinary Shares
12500
0
D
Performance Restricted Stock Units
2015-10-05
4
A
0
7500
0
A
Ordinary Shares
7500
7500
D
This RSU award is fully vested in accordance with its terms.
Each performance restricted stock unit represents a contingent right to receive one ordinary share of Alkermes plc.
Represents the earned but unvested portion of the performance restricted stock units granted to the reporting person on March 3, 2014. Fifty percent of the earned performance restricted stock units vested on October 5, 2015 and are included in Table I of this Form 4; the remaining fifty percent of the earned performance restricted stock units are included in Table II of this Form 4 and will vest on October 5, 2016. The performance restricted stock units were earned based on the Food and Drug Administration's approval of ARISTADA? (aripiprazole lauroxil).
/s/ Jennifer Baptiste, attorney-in-fact for Shane Cooke
2015-10-07